REFERENCES
- Choi SC, Marmarou A, Bullock R, et al. Primary endpoints in Phase III trials of severe head trauma: DRS versus GOS. J Neurotrauma, 1998; 15: 771–776
- Choi SC. Sample size in clinical trials with dichotomous endpoints: Use of covariables. J Biopharm Stat 1998; 8: 367–375
- O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549-556
- Whitehead J, Stratton I. Group sequential clinical trials with triangular continuation regions. Biometrics 1983; 39: 227–236
- Ederer P. Practical problems in collaborative clinical trials. Am J Epidemio 11975; 102: 111-118
- Sylvester RJ, Pinedo HM, Depauw N, et al. Quality of institutional participation in multicenter clinical trials. N Eng1J Med 1981; 305: 852–855
- Bracken MB. Methodological issues in the design of traumatic brain injury Phase III trials: A call for larger, simpler trials. Neurosurgery 2001 (in press)
- Doppenberg E, Bullock R. Clinical neuroprotection trials in severe traumatic brain injury: Lessons from previous studies. J Neurotrauma 1997; 14: 71–79